Blog
Pancreatic tumor markers: role in early diagnosis and disease control
Relevance of the problem
Pancreatic tumors, in particular adenocarcinoma, have high mortality due to late detection and lack of specific symptoms in the early stages. One way to improve early diagnosis is to use of tumor markers, which are detected in the patient's blood or tissues.
Tumor markers themselves is not a diagnosis, but allow:
suspect a malignant process;
track the effectiveness of treatment;
detect relapse;
assess the prognosis.
Main markers used in suspected pancreatic cancer
| Marker name | Full name | Diagnostic value |
|---|---|---|
| CA 19-9 | Carbohydrate Antigen 19-9 | The most widely used marker for prostate cancer |
| CEA | Carcinoembryonic Antigen | Less specific, useful for monitoring |
| CA 125 | Cancer Antigen 125 | Often increases with tumor spread |
| DUPAN-2 | Pancreatic cancer-associated | May be elevated in early stages |
| MIC-1 | Macrophage Inhibitory Cytokine | New promising marker |
CA 19-9 is basic, but not universal
CA 19-9 is a carbohydrate antigen synthesized by epithelial cells. Its levels are increased in 70–90% patients with pancreatic adenocarcinoma.
Norm: up to 37 U/ml
Significant increase (>1000 U/ml) often indicates an advanced stage
Limitation: not detected in 5–10% people (lack of Lewis antigen); may be elevated in cholestasis, cirrhosis, pancreatitis
Other markers: supporting role
CEA often used in conjunction with CA 19-9 to increase sensitivity. Although it is not specific, its parallel increase together with CA 19-9 may indicate disease progression.
CA 125 is used not only in gynecological oncology. Its increase in pancreatic cancer associated with metastases to the abdominal cavity.
MIC-1 — a relatively new marker, promising in early diagnosis, but not yet implemented in clinical routine.
Combined use
No marker is perfect. But combination of CA 19-9, CEA and CA 125:
increases diagnostic sensitivity up to 85%;
allows better control relapses;
allows assess response to chemotherapy.
How to interpret the results?
| Marker | Possible interpretation of the increase |
|---|---|
| CA 19-9 | Pancreatic cancer, cholangiocarcinoma, cholestasis, pancreatitis |
| CEA | Stomach, colon, lung cancer, smoking |
| CA 125 | Ovarian cancer, peritonitis, cirrhosis, inflammation |
High scores only make sense in combination with clinical and imaging methods (ultrasound, CT, MRI, ERCP, biopsy).
In what cases are pancreatic tumor markers prescribed?
Suspicion of tumor of the head of the pancreas with jaundice
Detection of neoplasms on ultrasound/CT
Postoperative follow-up (recurrence assessment)
Monitoring effectiveness of chemotherapy
Search relapse with an increase in markers after remission
Prospects: biomarkers of the future
Under investigation multidisciplinary approaches: genetic panels, circulating tumor DNA, liquid biopsy, microRNA. Their use will allow for future cancer detection before symptoms appear, when surgical intervention is still possible.
Pancreatic tumor markers are early warning and monitoring tool, but not an independent diagnosis. Their meaning becomes meaningful only in the system: clinic + imaging + histology. Timely determination CA 19-9 or CEA can change the trajectory of the disease — so it is important not to delay seeing a doctor, especially if there are risk factors.
